Literature DB >> 18435563

Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.

Rodrigo Machado-Vieira1, Giacomo Salvadore, David A Luckenbaugh, Husseini K Manji, Carlos A Zarate.   

Abstract

OBJECTIVE: Current therapeutics of depression are similar in their time to antidepressant action and often take weeks to months to achieve response and remission, which commonly results in considerable morbidity and disruption in personal, professional, family, and social life, as well as risk for suicidal behavior. Thus, treatment strategies presenting a rapid improvement of depressive symptoms--within hours or even a few days--and whose effects are sustained would have an enormous impact on public health. This article reviews the published data related to different aspects of rapid improvement of depressive symptoms. DATA SOURCES: Literature for this review was obtained through a search of the MEDLINE database (1966-2007) using the following keywords and phrases: rapid response, antidepressant, time to, glutamate, sleep, therapeutics, latency, and depression. The data obtained were organized according to the following topics: clinical relevance and time course of antidepressant action, interventions showing evidence of rapid response and its potential neurobiological basis, and new technologies for better understanding rapid anti-depressant actions. DATA SYNTHESIS: A limited number of prospective studies evaluating rapid antidepressant actions have been conducted. Currently, only a few interventions have been shown to produce antidepressant response in hours or a few days. The neurobiological basis of these rapid antidepressant actions is only now being deciphered.
CONCLUSIONS: Certain experimental treatments can produce antidepressant response in a much shorter period of time than existing medications. Understanding the molecular basis of these experimental interventions is likely to lead to the development of improved therapeutics rather than simply furthering our knowledge of current standard antidepressants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435563      PMCID: PMC2699451          DOI: 10.4088/jcp.v69n0610

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  145 in total

1.  The role of primary care in the treatment of depression.

Authors:  R M Hirschfeld
Journal:  Am J Manag Care       Date:  2000-02       Impact factor: 2.229

2.  Effects of sleep deprivation on serotonergic neuronal activity in the dorsal raphe nucleus of the freely moving cat.

Authors:  J P Gardner; C A Fornal; B L Jacobs
Journal:  Neuropsychopharmacology       Date:  1997-08       Impact factor: 7.853

3.  Actigraphy in patients with seasonal affective disorder and healthy control subjects treated with light therapy.

Authors:  Dietmar Winkler; Edda Pjrek; Nicole Praschak-Rieder; Matthäus Willeit; Lukas Pezawas; Anastasios Konstantinidis; Jürgen Stastny; Siegfried Kasper
Journal:  Biol Psychiatry       Date:  2005-08-15       Impact factor: 13.382

4.  Can the effects of antidepressants be observed in the first two weeks of treatment?

Authors:  M M Katz; C Bowden; P Stokes; R Casper; A Frazer; S H Koslow; J Kocsis; S Secunda; A Swann; N Berman
Journal:  Neuropsychopharmacology       Date:  1997-08       Impact factor: 7.853

5.  In vivo evaluation by differential pulse voltammetry of the effect of thyrotropin-releasing hormone (TRH) on dopaminergic and serotoninergic synaptic activity in the striatum and nucleus accumbens of the rat.

Authors:  F Crespi; P E Keane; M Morre
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

6.  Thyrotropin-releasing hormone selectively depresses glutamate excitation of cerebral cortical neurons.

Authors:  L P Renaud; H W Blume; Q J Pittman; Y Lamour; A T Tan
Journal:  Science       Date:  1979-09-21       Impact factor: 47.728

7.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

Review 8.  Pindolol augmentation of antidepressant response.

Authors:  Francesc Artigas; Albert Adell; Pau Celada
Journal:  Curr Drug Targets       Date:  2006-02       Impact factor: 3.465

9.  How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo.

Authors:  G D Tollefson; S L Holman
Journal:  Int Clin Psychopharmacol       Date:  1994       Impact factor: 1.659

10.  Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy.

Authors:  R H Segman; B Shapira; M Gorfine; B Lerer
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

View more
  63 in total

1.  ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.

Authors:  Golam M I Chowdhury; Kevin L Behar; William Cho; Monique A Thomas; Douglas L Rothman; Gerard Sanacora
Journal:  Biol Psychiatry       Date:  2011-12-09       Impact factor: 13.382

Review 2.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 3.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 4.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

5.  A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.

Authors:  Lobna Ibrahim; Nancy Diaz Granados; Libby Jolkovsky; Nancy Brutsche; David A Luckenbaugh; W Joseph Herring; William Z Potter; Carlos A Zarate
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

Review 6.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 7.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

8.  Ketamine Increases Proliferation of Human iPSC-Derived Neuronal Progenitor Cells via Insulin-Like Growth Factor 2 and Independent of the NMDA Receptor.

Authors:  Alessandra Grossert; Narges Zare Mehrjardi; Sarah J Bailey; Mark A Lindsay; Jürgen Hescheler; Tomo Šarić; Nicole Teusch
Journal:  Cells       Date:  2019-09-24       Impact factor: 6.600

Review 9.  Suicidal ideation during antidepressant treatment: do genetic predictors exist?

Authors:  Nader Perroud
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

10.  High expectancy and early response produce optimal effects in sertraline treatment for post-traumatic stress disorder.

Authors:  Belinda Graham; Natalia M Garcia; Mark S Burton; Andrew A Cooper; Peter P Roy-Byrne; Matig R Mavissakalian; Norah C Feeny; Lori A Zoellner
Journal:  Br J Psychiatry       Date:  2018-10-25       Impact factor: 9.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.